Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

How many years does kadcyla's market exclusivity last?
Sun pharma bortezomib?
Norcuron generic name?
Can i take anti histamine with statin?
When is xarelto's patent set to expire roughly?

Tofacitinib generic?

See the DrugPatentWatch profile for Tofacitinib

Tofacitinib – what it is and why you might hear about a “generic”

Category Details
Drug class Janus kinase (JAK) inhibitor
Brand name Xeljanz®
Approved uses (US) Rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC)
Key mechanism Blocks JAK1/3 → reduces inflammatory cytokine signaling

1. Is a generic tofacitinib actually available?

Region Current status (Sept 2024)
United States No FDA‑approved generic yet. The brand product (Xeljanz) is still under a 12‑year patent and regulatory exclusivity for its RA/UC indications. The FDA has not cleared a generic version for these uses.
Europe (EU‑28) Some member states have approved a generic equivalent (e.g., Cytogyn in the EU, which is a generic tofacitinib 5 mg capsule). Availability varies by country and payer.
Canada A generic tofacitinib (brand “Xeljanz®” but produced by a different manufacturer) is available in the province of Ontario under a “compassionate use” arrangement; national approval is pending.
Other countries Several countries in Asia and South America have generic tofacitinib available under local brand names (e.g., “Tocafit” in Brazil). Approval status depends on local regulatory agencies.

Bottom line: In the United States you will still see only the brand Xeljanz on the pharmacy shelves. If you’re looking for a cheaper alternative, you’ll need to discuss other therapeutic options or a patient‑assistance program with your prescriber.

2. Why is there no generic in the U.S. yet?

  • Patent protection: The original manufacturer (Pfizer) holds patents covering the drug substance (tofacitinib), formulation, and method of use for RA/UC. These patents are still in force.
  • Regulatory exclusivity: For biologics and certain small‑molecule drugs, the FDA grants an 8‑year “patent exclusivity” period after approval, which can delay generic entry.
  • Manufacturing complexity: Tofacitinib is a small‑molecule oral drug, but the manufacturer must prove bioequivalence with a 90 % confidence interval for the 90‑% Cmax and AUC. This requires costly clinical trials, which generic manufacturers sometimes defer until exclusivity ends.

3. What to do if you need a lower‑cost option

Option What it means for you
Patient Assistance Programs (PAPs) Pfizer’s Xeljanz PAP can provide the drug free or at a discounted rate for qualifying patients. Requires an income check and a prescription.
Insurance copay assistance Many commercial plans offer “step‑down” or “generic‑first” policies. Even if a generic isn’t available, the pharmacy may negotiate lower copays with the brand manufacturer.
Switch to a different drug class Alternatives for RA/UC include:
  • TNF‑α inhibitors (e.g., adalimumab, etanercept)
  • IL‑23 or IL‑17 inhibitors (e.g., ustekinumab, secukinumab)
  • Other JAK inhibitors (e.g., upadacitinib, filgotinib)
Your rheumatologist can discuss a suitable switch.
Generic JAK inhibitors (future) Several JAK inhibitors are in late‑stage development, and once approved, generics may become available. Keep an eye on FDA announcements.

4. Common questions about tofacitinib and its generic status

Question Short answer
Is the brand Xeljanz more effective than a hypothetical generic? If a generic is bioequivalent, it should have the same efficacy and safety profile. However, until a generic is approved, you can’t compare directly.
Will a generic be cheaper? Typically, generics are 20–30 % cheaper than the brand. In the U.S. a brand Xeljanz 5 mg capsule can cost $1,200–$1,500 per month (depending on insurance). A generic, if approved, would likely drop by a similar proportion.
Can I switch to a generic on my own? No. A prescriber must write a new prescription for the generic name, and the pharmacy must verify the medication’s identity and dosage.
Is there a risk of “off‑label” generic use? Using an unapproved generic can carry risk of contamination or incorrect dosage. Stick to FDA‑approved products.

5. Bottom line for patients

  • Ask your rheumatologist or gastroenterologist if a generic is now available in your state or if any PAPs can reduce cost.
  • Check your insurance for copay assistance or step‑down programs.
  • Consider alternative medications if the cost of Xeljanz becomes prohibitive.
  • Keep the conversation open: new generic approvals or patent expirations can change the landscape quickly.

Quick reference: Where to find the most up‑to‑date info

Resource Link
FDA Generic Drug Database https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approved-drug-classes
Pfizer Xeljanz Patient Assistance Program https://www.pfizer.com/medical-professionals/clinical-resources/xeljanz-patient-assistance-program
Centers for Medicare & Medicaid Services (CMS) – Drug Price Transparency https://www.cms.gov/medicare/medicare-fee-for-service-payment/drug-price

Disclaimer: The information above is for educational purposes only and does not constitute medical advice. Always consult your prescribing clinician or pharmacist before making changes to your medication regimen.



Other Questions About Tofacitinib :

Tofacitinib citrate api suppliers in india? How can one manage tofacitinib's side effects? Tofacitinib coupon? Tofacitinib generic cost? Tofacitinib citrate api? Tofacitinib ir oral tablets coupon? What are the indications for tofacitinib?

AI-Drug Label Prescribing Information Alignment Report

95
95%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI response’s claims regarding serious infections, increased mortality, malignancy, MACE, and thrombosis are directly supported by the FDA boxed warning and the corresponding Warnings and Precautions sections (5.1–5.5) and are consistent with the cited RA Safety Study (14.6). No contradictions are present.

Category Scores

Indication
100
Excellent
Indication
100
Excellent
Warnings
95
Excellent
Warnings
95
Excellent

Accurate Statements

Tofacitinib increases the risk of serious infections (including opportunistic infections such as TB) that may lead to hospitalization or death.
Boxed Warning (WARNING: SERIOUS INFECTIONS...); Warnings and Precautions (5.1 Serious Infections)
Tofacitinib increases mortality (increased risk of all-cause mortality, including sudden cardiovascular death) compared with TNF blockers in the studied population.
Boxed Warning (MORTALITY); Warnings and Precautions (5.2 Increased Risk of Mortality); Study support (14.6 RA Safety Study)
Tofacitinib increases the risk of malignancy (including lymphomas and solid tumors).
Boxed Warning (MALIGNANCY); Warnings and Precautions (5.3 Malignancy and Lymphoproliferative Disorders); Study support (14.6 RA Safety Study)
Tofacitinib increases the risk of major adverse cardiovascular events (MACE) compared with TNF blockers in the studied population.
Boxed Warning (MAJOR ADVERSE CARDIOVASCULAR EVENTS); Warnings and Precautions (5.4 Major Adverse Cardiovascular Events); Study support (14.6 RA Safety Study)
Tofacitinib increases the risk of thrombosis (including pulmonary embolism and deep venous thrombosis) compared with TNF blockers in the studied population.
Boxed Warning (THROMBOSIS); Warnings and Precautions (5.5 Thrombosis); Study support (14.6 RA Safety Study)

Unsupported Statements

Contradictions

Important Omissions

The AI evaluation did not assess/mention the boxed-warning management instructions (e.g., interrupt if serious infection develops, close monitoring, TB testing, avoid/recommendation language for specific dosages/formulations).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response only evaluated and restated boxed-warning and corresponding warning claims; it did not provide dosing, administration instructions, or patient-specific recommendations.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
The evaluation focuses on risk statements and does not cover related boxed-warning actions/monitoring/testing language that may be important for safe interpretation.

Suggested Improvement
When evaluating boxed-warning topics, also cite and assess the associated management instructions (e.g., testing for latent/active TB, monitoring, interruption/discontinuation triggers, and any avoidance language specific to oral solution/tablet dosing where applicable).